Abstract
Overexpression of alpha synuclein has been implicated in Parkinson's disease (PD), therefore pharmacological approaches that drive to stimulate the breakdown or degradation of the clusters of alpha synuclein might give a hope in attenuating the progression of the disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
